Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
LAB 
Standard Biotools Inc (LAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: LAB (1-star) is a SELL. SELL since 4 days. Simulated Profits (-7.69%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.55
1 Year Target Price $1.55
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.38% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 492.24M USD | Price to earnings Ratio - | 1Y Target Price 1.55 |
Price to earnings Ratio - | 1Y Target Price 1.55 | ||
Volume (30-day avg) 3 | Beta 1.26 | 52 Weeks Range 0.92 - 2.14 | Updated Date 01/8/2026 |
52 Weeks Range 0.92 - 2.14 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -75.56% | Operating Margin (TTM) -29.42% |
Management Effectiveness
Return on Assets (TTM) -14.55% | Return on Equity (TTM) -33.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 324729729 | Price to Sales(TTM) 2.9 |
Enterprise Value 324729729 | Price to Sales(TTM) 2.9 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA -19.22 | Shares Outstanding 384565414 | Shares Floating 46147570 |
Shares Outstanding 384565414 | Shares Floating 46147570 | ||
Percent Insiders 2.57 | Percent Institutions 76.75 |
Upturn AI SWOT
Standard Biotools Inc
Company Overview
History and Background
Standard Biotools Inc. was formed in February 2023 through the business combination of SOMA SCAN INC. and Standard BioTools Inc. (formerly known as Bio-Rad Laboratories' Clinical Diagnostics Group). This merger aimed to create a comprehensive platform for single-cell analysis and spatial biology. The company's roots can be traced back to the innovation and development in these specialized fields within their respective predecessor entities.
Core Business Areas
- Single-Cell Genomics: Focuses on providing tools and technologies for the precise analysis of individual cells, enabling researchers to understand cellular heterogeneity, gene expression, and cellular function at an unprecedented resolution.
- Spatial Biology: Offers solutions that allow researchers to analyze biological samples while preserving the spatial context of cells and their interactions within tissues. This is crucial for understanding disease mechanisms and drug discovery.
Leadership and Structure
Standard Biotools Inc. is led by a management team with experience in the life sciences and diagnostics industries. The organizational structure is designed to support innovation and commercialization across its core business segments, integrating the expertise from its predecessor companies.
Top Products and Market Share
Key Offerings
- Product Name 1: The SomaScan Assay and SomaCode platform. This platform offers high-throughput, sensitive, and quantitative analysis of proteins in complex biological samples. It is used in drug discovery, biomarker research, and diagnostics. Competitors include Olink, Quanterix, and NanoString Technologies in the proteomics space. Specific market share data for this individual product is not publicly disclosed, but it's a central offering of the combined entity.
- Product Name 2: The Fluidigm portfolio, including instruments and consumables for single-cell genomics and spatial biology applications. This includes microfluidic devices for sample preparation and analysis. Competitors include 10x Genomics, Thermo Fisher Scientific, and Illumina in the single-cell and spatial analysis markets. Market share figures are not precisely detailed for each sub-product but represent a significant portion of the company's revenue.
Market Dynamics
Industry Overview
The life sciences tools and diagnostics market is characterized by rapid technological advancements, increasing demand for precision medicine, and a growing focus on understanding complex biological systems at the cellular and molecular level. Key trends include the rise of single-cell analysis, spatial biology, and high-throughput proteomics.
Positioning
Standard Biotools Inc. is positioned as a provider of integrated solutions for single-cell and spatial biology, as well as proteomics. Its competitive advantage lies in its ability to offer a comprehensive suite of technologies that address critical research needs across multiple modalities, potentially offering synergies for researchers.
Total Addressable Market (TAM)
The total addressable market for single-cell analysis, spatial biology, and proteomics is estimated to be in the tens of billions of dollars, with strong growth projections driven by advancements in genomics, drug discovery, and diagnostics. Standard Biotools Inc. aims to capture a significant share of this market by offering a unique combination of technologies and expertise.
Upturn SWOT Analysis
Strengths
- Integrated platform for single-cell and spatial biology.
- Established proteomics technology (SomaScan).
- Experienced leadership team from predecessor companies.
- Potential for synergistic offerings.
Weaknesses
- Integration challenges post-merger.
- Brand recognition for the combined entity is nascent.
- Dependence on innovation and R&D investment.
- Competition from established players.
Opportunities
- Growing demand for single-cell and spatial analysis in drug discovery and diagnostics.
- Expansion into new therapeutic areas and markets.
- Strategic partnerships and collaborations.
- Leveraging AI and machine learning for data analysis.
Threats
- Intense competition and rapid technological obsolescence.
- Economic downturns impacting R&D budgets.
- Regulatory hurdles for new diagnostic applications.
- Challenges in scaling production and distribution.
Competitors and Market Share
Key Competitors
- 10x Genomics (TXG)
- Thermo Fisher Scientific (TMO)
- Illumina (ILMN)
- Olink Holding AB (OLK)
- Quanterix (QTRX)
Competitive Landscape
Standard Biotools Inc. operates in a highly competitive landscape with established players and innovative startups. Its advantage lies in its integrated platform approach, potentially offering a more complete solution for researchers compared to single-focus competitors. However, it faces challenges in market penetration and establishing brand dominance against larger, more diversified companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be assessed by examining the performance of SOMA SCAN INC. and Bio-Rad's Clinical Diagnostics Group prior to the merger, particularly in their respective specialized markets.
Future Projections: Future growth projections are expected to be driven by the expansion of single-cell and spatial biology markets, the success of product integration, and the company's ability to capture market share with its comprehensive offerings. Analyst consensus on future revenue and earnings will be a key indicator.
Recent Initiatives: The primary recent initiative is the business combination itself, forming Standard Biotools Inc. Future initiatives will likely focus on integrating operations, cross-selling products, and continued investment in R&D to maintain a competitive edge.
Summary
Standard Biotools Inc. is a newly formed entity combining expertise in single-cell genomics, spatial biology, and proteomics. Its strength lies in offering a comprehensive platform and leveraging established technologies. However, it faces challenges in integration, market positioning, and intense competition. Continued innovation, strategic partnerships, and successful execution of its integration strategy will be crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials.
- Industry analysis reports.
- Financial data providers (e.g., Bloomberg, Refinitiv - where applicable for predecessor entities or general market data).
Disclaimers:
This JSON output is based on publicly available information as of the last update. Financial data and market share figures are estimates and subject to change. This information is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Standard Biotools Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2003-07-29 | President, CEO & Director Dr. Michael Egholm Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 814 | Website https://www.standardbio.com |
Full time employees 814 | Website https://www.standardbio.com | ||
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.